

17/FEB/SE/2019/GBSL

CIN No. L24100MH1984LC033519

14th February, 2019

To
The Manager (CRD)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001

To
The Manager
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code : 509079

Symbol : GUFICBIO

Dear Sirs,

Sub: Outcome of the Board of Directors Meeting held for the quarter and nine months ending December 31, 2018

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on 13th February, 2019 inter alia considered and approved the Un-audited Financial Results of the Company for the Quarter and Nine months ended December 31, 2018.

In terms of provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following:

- A copy of the Un-Audited Financial Results for the Quarter and Nine months ended December 31, 2018.
- Limited Review Report received from the Statutory Auditor of the Company on the Un-Audited Financial Results for the Quarter and Nine months ended December 31, 2018.

The meeting of the Board of Directors commenced on February 13, 2019 at 4.30 p.m. and concluded next day i.e., on February 14, 2019 at 4.40 a.m.

Kindly take the same on your record.

Thanking You,

Yours Faithfully,
For Gufic Biosciences Limited


Ami Shah
Company Secretary
Membership No. A39579



GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069
(CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - info@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs. in Lakhs except EPS)

Statement of Standalone Unaudited Financial Results for the Quarter and Nine months Ended December 31, 2018


Sr. No.	Particulars	Quarter Ended			Nine months ended		Year ended
		31-Dec-18	31-Dec-17	30-Sep-18	31-Dec-18	31-Dec-17	31-Mar-18
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	INCOME						
a	Revenue from operations						
b	Other Income	8765.29	8961.38	9242.09	25885.58	22,959.00	31,037.81
	Total Income	22.57	65.94	69.79	125.13	162.22	309.72
2	Expenses	8787.86	9027.32	9311.88	26010.71	23121.22	31347.53
a	Cost of Materials consumed	0					
b	Purchase of stock-in-trade	3025	3885.24	4521.49	10878.02	8712.95	11,412.89
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	1444.06	1265.75	873.67	2900.39	5014.34	6,745.56
d	Excise duty on Sale of Goods	(27.81)	(690.84)	(124.62)	(159.58)	(2682.07)	(3317.06)
e	Employee benefits expense	0	0.00	0.00	0	315.52	315.52
f	Finance Cost	1503.31	1440.34	1276.93	4260.99	3771.24	5,744.46
g	Depreciation and amortisation expense	234.94	173.50	246.94	674.22	619.80	890.61
h	Other expenses	105.16	117.38	100.70	300.6	313.22	437.77
	Total Expenses	1624.39	1818.73	1465.08	4695.99	4874.03	6,281.11
3	Total Profit / (Loss) before exceptional and tax (1-2)	7909.05	8010.10	8360.19	23550.63	20,939.03	28,510.86
4	Exceptional Items	878.81	1017.22	951.69	2460.08	2,182.19	2,836.67
5	Total Profit / (Loss) Before Tax	0				158.88	158.88
6	Tax expense	878.81	1017.22	951.69	2460.08	2,341.07	2,995.55
	Current Tax	0					
	Deferred Tax	320.82	396.10	333.93	840.08	900.10	1,101.40
	Short/(excess) Tax Provisiopn of Earlier Years	(27.67)	(8.13)	(0.40)	46.71	(101.61)	120.43
	Total Tax Expenses	(2.37)	0.00	(0.54)	(2.37)		125.95
7	Net Profit/(Loss) for the period from continuing operations	290.78	387.97	332.99	884.42	798.49	1,347.78
8	Total Profit (Loss) for period	588.03	629.27	618.70	1575.66	1542.58	1647.77
9	Other Comprehensive Income (net of taxes)	588.03	629.27	618.70	1575.66	1,542.58	1,647.77
10	Total Comprehensive Income	0	(0.51)	-		(0.51)	(2.10)
11	Reserves	588.03	628.76	618.70	1575.66	1,542.07	1,645.67
12	Details of Equity Share Capital						4,631.75
	Paid-up equity share capital						
	Face Value of equity share capital (Rs.)	778.3	778.30	778.30	778.30	778.30	778.30
13	Earning per equity share	1	1.00	1.00	1.00	1.00	1.00
i	Basic earnings/(loss) per share from continuing and discontinued operations	0.76	0.81	0.79	2.02	1.98	2.11
ii	Diluted earnings/(loss) per share from continuing and discontinued operations	0.76	0.81	0.79	2.02	1.98	2.11



NOTES

1	The above Results for the quarter and nine months ended December 31, 2018 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 13, 2019. The Statutory Auditors have carried out limited review of the results for quarter and nine months ended December 31, 2018
2	Previous Period/Year's figures have been regrouped /reclassified wherever necessary.
3	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with rules issued thereunder.
4	The Board of Directors at its meeting held on September 20, 2018 approved the scheme of Amalgamation of Gufic Lifesciences Private Limited (the Transferor Company) with the Company and their respective shareholders and creditors, subject to shareholders and regulatory approvals.
5	The Company does not monitor the different segments separately and thus the total business is treated as one segment i.e., Pharmaceuticals
6	With respect to the modified opinion by the Statutory Auditors in the Limited Review Report as enclosed herewith, the Management response on the same are as follows : <ul style="list-style-type: none">• The Company has plans to validate the new ERP system vis a vis the primary accounting system and plans to switch to the new system exclusively by April, 2019.• Management has initiated the process of reconciliation of physical inventory vis a vis inventory report from ERP system and the Management is expected to conclude the same by March 2019. The Management is of view that the report generated from ERP system is accurate and do not expect any material differences.• The Company has already initiated the process of balance confirmation of Trade Receivables & Trade Payables and the management is confident that a comprehensive confirmation as required by Statutory Auditors would be concluded before the end of March, 2019.• The GST reconciliation is also in progress and the same it is expected to be completed before the year ending March 31, 2019. The Management is of the view that there would be no major impact due to pending reconciliation• The Board of Directors understanding the business interest of the Company and the shareholder's concern, at its Board Meeting held on February 01, 2019 has already initiated a Postal Ballot for Approval of Related Party Transactions with Gufic Lifesciences Private Limited to a tune of Rs. 75.00 crores for the financial year 2018-19, the results of which shall be announced by 14th March, 2019 which will ratify the related party transactions during the year.

Place : Mumbai
Date : 14.02.2019

Signed for verification

by SHR & CO
Mumbai

For Gufic Biosciences Limited



Hemal M. Desai
Whole Time Director
DIN:07014744

Certificate No: SHR/GBSL/1073/18 - 19

CERTIFICATE

The
Board of Directors
Gufic Biosciences Limited
Mumbai

1. Introduction

We have reviewed the accompanying statement of unaudited financial results of **GUFIC BIOSCIENCES LIMITED ("the Company")** for the quarter and nine months ended **December 31, 2018**, attached herewith, (the "Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 (the "Act"), read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. Scope of Review

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Basis for Modified Opinion

- a. The company has switched over to new ERP system on account of introduction of Goods and Service Tax (GST). The said system is under implementation stage and accuracy of which are yet to be tested by management. The unaudited accounts for the quarter and nine months ended December 31, 2018 has been compiled from primary as well subsidiary or other records maintained by the management, accuracy of which are yet to be tested.



- b. The company has recorded inventories as at December 31, 2018 based on certain reports generated from ERP system and also after making certain adjustments. Pending testing of accuracy of system and availability of appropriate audit evidences, we are unable to express our view in respect of carrying value of inventories considered in arriving at the financial results for the quarter and nine months ended December 31, 2018.
- c. Balance of Trade Receivable and Trade Payable are subject to confirmations, verification and adjustments necessary upon reconciliation thereof. Adjustments required upon such confirmations, if any, are not ascertainable and hence not provided for.
- d. We have not been provided with reconciliation of purchase, sales, input credits shown in books of account with GST return filed. Hence, we are unable to comment on effect of the same on the unaudited financial results for the quarter and nine months ended December 31, 2018 of the company pending such reconciliation.
- e. The company has entered into transaction with related party for Sales of Rs. 616.80 lakhs, labour charges received of Rs. 5.83 lakhs, Purchase of Rs. 2191.53 lakhs, labour charges paid of Rs. 960.70 lakhs and also advance of Rs. 149.70 lakhs which has not been approved by the shareholders under section 188 of the companies Act ("the Act"). We have been informed that the company has put up a resolution once again to the shareholders for ratifying the said transactions. If the said transactions are not ratified then the same is required to be reversed as per section 188 of the Act and will have consequential impact on the unaudited financial results for the quarter as well as for the nine months ended December 31, 2018.

As a result of our observations given in para 3(a) to 3(e) above, we are unable to ascertain cumulative impact on the financial results for the quarter ended and also for the nine months period ended December 31, 2018.


4. Other Matter

- (a) The company has received an order dated September 6, 2018, from the National Company Law Tribunal for merger of Gufic Stridden Bio Pharma Private Limited (Transferor) with the company from the appointed date i.e. April 1, 2016. Pursuant to the said order the unaudited result of the quarter ended December 31, 2017 and for the nine months ended December 30, 2017 have been incorporated based on the management certified financial statements of the transferor company.
- (b) As per the information and explanation given by the management the difference segment of the company are not monitored separately and hence the total business needs to be treated as one segment.

5. Conclusion

Based on our review conducted as above and subject to our comments given above in para 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results has not been prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. Including the manner in which it is to be disclosed or that it contains any material misstatement.

For S H R & CO
Chartered Accountant
FRN: 120491W


Deep N Shroff
Partner

M. No: 122592

Mumbai dated February 14, 2019

